1. Background {#sec0005}
=============

Inadequate intake of vitamins is common \[[@bib0005]\] and has a detrimental effect on normal immune function \[[@bib0010]\]. Multivitamin supplementation at the recommended dietary allowance level thus can improved cellular immune parameters and reduce the risk of infections \[[@bib0015]\]. Multivitamins are frequently used by the general population \[[@bib0020]\], and are also frequently recommended by naturopaths \[[@bib0025]\]. The aim of this rapid review was to assess the effects of multivitamin supplementation on acute respiratory tract infections (ARTI) and associated complications.

2. Methods {#sec0010}
==========

The rapid review protocol was created a prioiri and not changed during the conduct of the review.

2.1. Research Question {#sec0015}
----------------------

What are the effects of multivitamin supplementation on acute respiratory tract infections (ARTI) and associated complications?

Inclusion/exclusion criteria1)**Participants:** Adult humans with an acute respiratory tract infection2)**Intervention:**a)Multivitamin supplementation orb)Multivitamin supplementation in combination with conventional care3)**Control:**a)No treatmentb)Placeboc)Conventional care alone4)**Outcomes:**a)Mortalityb)Duration of symptomsc)Responder ratesd)Number of days in hospitale)Number of patients with adverse eventsf)Any other reasonable clinical outcome5)**Study type:**a)Randomized controlled trials orb)randomized cross-over trials

2.2. Databases {#sec0020}
--------------

Medline (Ovid), AMED (Ovid), CINAHL (EBSCO), EMBASE (Ovid) were searched from their inception through May 11, 2020.

2.3. Search terms (example) {#sec0025}
---------------------------

The search strategy for Medline is shown in [Table 1](#tbl0005){ref-type="table"} .Table 1Complete search strategy for Medline.Table 11Randomized Controlled Trials as Topic/2randomized controlled trial/3Random Allocation/4Double Blind Method/5Single Blind Method/6clinical trial/7clinical trial, phase i.pt.8clinical trial, phase ii.pt.9clinical trial, phase iii.pt.10clinical trial, phase iv.pt.11controlled clinical trial.pt.12randomized controlled trial.pt.13multicenter study.pt.14clinical trial.pt.15exp Clinical Trials as topic/16or/1-1517(clinical adj trial\$).tw.18((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw.19PLACEBOS/20placebo\$.tw.21randomly allocated.tw.22(allocated adj2 random\$).tw.23or/17-222416 or 2325case report.tw.26letter/27historical article/28or/25-272924 not 2830multivitamin\$.af.31Influenza, Human/ or Influenza A Virus, H1N1 Subtype/ or Influenza A virus/ or Influenza A Virus, H3N2 Subtype/ or H1N1.mp.32MERS-COV.mp. or Middle East Respiratory Syndrome Coronavirus/3331 or 323429 and 30 and 3335(breathing or lung or pulmonary or respir\$).af.3631 or 32 or 353729 and 30 and 36

2.4. Study selection and data extraction {#sec0030}
----------------------------------------

Two review authors independently screened titles, abstracts and full-texts. Data were extracted from each paper by one review author, with two authors sharing data extraction across the included papers.

2.5. Risk of Bias Assessment {#sec0035}
----------------------------

The risk of bias (RoB) of study findings in each included paper was assessed by one review author using the revised Cochrane RoB tool for randomised trials (RoB 2) (<https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2?authuser=0>). Two authors undertook this task for the included manuscripts.

3. Results {#sec0040}
==========

3.1. Description of included studies {#sec0045}
------------------------------------

The search identified 233 citations, including 36 duplicates. The remaining 198 citations were screened by title and abstract against the inclusion and exclusion criteria, and 180 citations were excluded. The full text of 18 citations were assessed for eligibility and 11 were excluded as they sampled the wrong population (n = 3), were not reporting original research (n = 2), reported a different outcome (n = 2), were retracted (n = 2), or used the wrong intervention or study design (n = 2). The remaining seven studies were included in this rapid review.

All seven included studies were randomised controlled trials. Six studies were described as double-blind. \[[@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055]\]. The level of blinding in the remaining study was not defined \[[@bib0060]\].

Most (n = 5) studies were undertaken in the World Health Organisation (WHO) European region; this included two studies in France, \[[@bib0035],[@bib0040]\] one each in the Netherlands \[[@bib0045]\], UK \[[@bib0030]\], and Germany \[[@bib0055]\]. The remaining studies were conducted in the WHO South-East Asia Region (i.e. India) \[[@bib0060]\] and the WHO Region of the Americas (i.e. Canada) \[[@bib0050]\].

The seven included studies comprised a total pool of 3,644 participants. Sample sizes ranged between 36 and 910. All participants were adults aged ≥18 years; six of seven studies recruited adults aged ≥50 years. \[[@bib0030], [@bib0035], [@bib0040],[@bib0055], [@bib0060], [@bib0065]\] Participants were recruited from the community in four studies \[[@bib0030],[@bib0055], [@bib0060], [@bib0065]\], and through institutional settings (i.e. hospital, residential care facility) in three \[[@bib0035],[@bib0040],[@bib0050]\].

Multivitamins were administered daily in oral form in all seven studies, either as tablets (n = 3) \[[@bib0030],[@bib0050],[@bib0055]\] or capsules (n = 4) \[[@bib0035], [@bib0040], [@bib0045],[@bib0060]\]. All interventions contained a combination of at least five vitamins and minerals. Treatment duration ranged from three months to two years, with a median duration of 15 months. Control groups received either matching placebo (n = 4) \[[@bib0035],[@bib0040],[@bib0050],[@bib0055]\], other vitamin/mineral combination (n = 2),[@bib0045],[@bib0060]\] sorbitol (n = 1)\[[@bib0030]\] or soybean oil (n = 1).[@bib0045]\]

3.2. Risk of bias {#sec0050}
-----------------

In the first Domain (randomisation process), four studies were rated as having low risk of bias, \[[@bib0030],[@bib0035],[@bib0045],[@bib0050]\] and three were assessed as having some risk of bias \[[@bib0040],[@bib0055],[@bib0060]\]. For Domain 2 (treatment assignment), most (n = 5) studies were determined to have low risk of bias \[[@bib0030],[@bib0035],[@bib0045], [@bib0050], [@bib0055]\], with one rated as having some risk of bias \[[@bib0040]\], and one identified as having high risk of bias \[[@bib0060]\]. Under Domain 3 (missing outcome data), all studies were assessed as having low risk of bias, except Jain (2002), which was rated as having high risk of bias \[[@bib0060]\]. For Domain 4 (measure of outcomes), all studies were rated as having low risk of bias. In Domain 5 (selective reporting), all trials were identified as having some risk of bias. Overall, one study was rated as having high risk of bias \[[@bib0060]\], while the remaining six studies were judged as having some risk of bias \[[@bib0030],[@bib0050],[@bib0055]\]. These judgements should be taken into consideration when interpreting the findings of this review.

3.3. Summary of findings {#sec0055}
------------------------

The seven included studies reported on ten distinct outcomes, including incidence of ARTI, severity of ARTI, infectious morbidity and symptoms, mortality rate, health service contact rate, quality of life, antibiotic use, micronutrient status, cellular immune response and adverse events (see [Table 2](#tbl0010){ref-type="table"} ).Table 2Summary details of studies examining the effects of multivitamins on acute respiratory tract infections and associated complicationsTable 2AuthorDateCountrySettingParticipantsInterventionComparisonOutcomes**Avenell et al**2005United KingdomCommunities associated with general practices910 men and women aged 65 years or over who did not take vitamins or mineralsDaily over 12 months (oral): Vitamin A (acetate) \[800 mcg\], Vitamin C \[60 mg\], Vitamin D \[5 mcg\], Vitamin E \[10 mg\], thiamin \[1.4 mg\], riboflavin \[1.6 mg\], niacin \[18 mg\], pantothenic acid \[6 mg\], pyridoxine \[2 mg\], B12 \[200 mcg\], iron\]14 mg\], iodine \[150 mcg\], copper \[0.75 mg\], zinc \[15 mg\], manganese \[1 mg}Sorbitol placebo-Number of contacts with primary care for infection (12 months)-Number of self-reported days of infection (12 months)-Quality of Life (12 months)-Number of antibiotic prescriptions in primary care (12 months)-Number of days that antibiotics were prescribed (12 months)-Number of hospital admissions (including those related to infection) (12 months)-Number of days in hospital with infection (12 months)-Number of infection-related and all outpatient visits (12 months)-Adverse events reported by participants (12 months)**Graat et al**2002NetherlandsCommunity652 men and women aged 60 years or overDaily over 15 months (oral): Retinol (600 mcg), beta-carotene (1.2 mg), ascorbic acid (60 mg), vitamin E (10 mg), cholecalciferol (5 mcg), vitamin K (30 mcg), thiamin (1.4 mg), riboflavin (1.6 mg), niacin (18 mg), pantothenic acid (6 mg), pyridoxine (2.0 mg), biotin (150 mcg), folic acid (200 mcg), cyanocobalamin (1 mcg), zinc (10 mg), selenium (25 mcg), iron (4.0 mg), magnesium (30 mg), copper (1.0 mg), iodine (100 mcg), calcium (74 mg), phosphor (49 mg), manganese (1.0 mg), chromium (25 mcg), molybdenum (25 mcg), silicium (2 mcg). (2) VE: 200 mg/dL. (3) MV+VE. (4) Placebo(1) Vitamin E; (2) MV+VE; (3) soybean oil-Incidence of acute respiratory tract infections (15 months)-Severity of acute respiratory tract infections (15 months)**Jain**2002IndiaCommunity36 adults aged 51--78 yearsDaily over 12 months (?) (oral): Vitamin A (400 RE), beta-carotene (16 mg), thiamin (2.2 mg), riboflavin (1.5 mg), niacin (16 mg), vitamin B6 (3.0 mg), folate (400 mcg), vitamin B12 (4.0 mcg), vitamin C (80 mg), vitamin D (4.0 mcg), vitamin E (44 mg), iron (16 mg), zinc (14 mg), copper (1.4 mg), selenium (20 mcg), iodine (200 mcg), calcium (200 mg), magnesium (100 mg)Calcium (200 mg), magnesium (100 mg)-Incidence of acute respiratory tract infections (12 months?)-Severity of acute respiratory tract infections (12 months?)**Girodon et al**1997FranceGeriatric centre81 elderly subjects in a geriatric centre, 84.17 ± 8.1 years (range 65--102 years; 20 males, 61 females) with no acute illness or history of cancer, and not taking medication that might interfere with nutritional status or immunocompetenceDaily over 2 years (oral): Trace elements (zinc sulfate equiv 20 mg zinc, selenium 100 ug as sulfide) OR Vitamins (ascorbic acid 120 mg, beta carotene 6 mg = 1000 retinol equivalents, alpha-tocopherol 15 mg OR Trace elements + VitaminsVisibly identical placebo (calcium phosphate and cellulose)-Micronutrient status (6 months, 1 year, and 2 years)-Respiratory and symptomatic urogenital infections (6 months, 1 year, and 2 years)-Deaths total (2 years)-Deaths from infection (2 years)**Girodon et al**1999France25 geriatric centres725 long-term institutionalised elderly patients aged 65 and over with no acute illness or history of cancer, and not taking medication that might interfere with nutritional status or immunocompetence.Daily over 2 years (oral): Trace elements (zinc sulfate equiv 20 mg zinc, selenium 100 ug as sulfide) OR Vitamins (ascorbic acid 120 mg, beta carotene 6 mg = 1000 retinol equivalents, alpha-tocopherol 15 mg OR Trace elements + VitaminsPlacebo - calcium phosphate and microcrystalline cellulose. Identical to intervention.-Delayed hypersensitivity skin response (6 months, 12 months)-Humoral response to influenza vaccine (injected 15 to 17 months after start of supplementation) (28, 90, 180, and 270 days)-Infectious morbidity and mortality (2 years)**Liu et al**2007Canada21 long-term care facilities (nursing homes)763 participants; 70% female. Mean age at entry 85 (65--103).Daily over 18 months plus 1 month run-in period (oral): Vitamin A 400 retionol equivalents, beta-carotene 16 mg, vitamin D 4 mg (160 IU), vitamin E44 mg (74 IU), vitamin C 80 mg, thiamin 2.2 mg, riboflavin 1.5 mg, niacin 16 mg, vitamin B63 mg, vitamin B124 mg, folate 400 mg, calcium (elemental) 200 mg, magnesium 100 mg, iron (elemental) 16 mg, iodine 200 mg, zinc 14 mg, copper 1.4 mg, and selenium 20 mg.Visibly identical placebo-Infections Total (blood stream, skin and soft tissue, gatroenteritis, respiratory tract (upper/lower/total), urinary tract. See table 3 for breakdown) (18 months)-Antibiotic use (18 months)-Rate of hospitalization (Emergency department visits/Hospital admissions) (18 months)**Winkler et al**2005GermanyRecruited by advertisements477 healthy volunteers aged 18--70 (36 ± 13) years, without known congenital or acquired immune defects, allergies or other chronic diseases and acute diseases requiring treatment, alcohol or drug misuse or both, pregnancy or lactation, interfering dietary habits or vaccination against influenza within the last 12 months.Daily over 3 to 5.5 months (oral):\
5 × 10^8^ cfu (colony-forming units) of the spray-dried probiotic bacteria with vitamins and minerals.Placebo - film-coated tablets with the same excipiemt ingredients, appearance, smell and taste. Details [Table 1](#tbl0005){ref-type="table"}.-Cellular immune response (14 days)-Single specific symptoms that appeared during the common cold episodes-Total symptom score expressing the overall severity of each episode (primary parameter)-Incidence and duration of common cold episodes

Four studies measured the incidence of ARTI \[[@bib0045], [@bib0050], [@bib0055], [@bib0060]\]. In all four studies, the difference between groups in the incidence of ARTI was not found to be statistically significant.

Duration of ARTI was examined in four studies \[[@bib0030],[@bib0045],[@bib0055],[@bib0060]\]. The study findings were inconsistent, with two studies reporting a statistically significant reduction in the duration of respiratory illness/ARTI symptoms \[[@bib0055],[@bib0060]\], and two studies reporting no difference between groups in the duration of ARTI \[[@bib0030],[@bib0065]\]. One study \[[@bib0065]\] did report a statistically significantly longer duration of ARTI symptoms among participants receiving multivitamin plus high-dose vitamin E when compared with placebo, but no difference was evident between multivitamin and placebo.

Two studies investigated infectious morbidity and symptoms; this included number of symptoms \[[@bib0045],[@bib0055]\], presence/duration of fever \[[@bib0055],[@bib0065]\], activity restriction \[[@bib0065]\], and total symptom score \[[@bib0055]\]. Studies reported a significant reduction in headache, conjunctivitis and activity restriction \[[@bib0045]\] in participants receiving multivitamins compared to placebo, but no difference between groups in total symptom score \[[@bib0055]\] or number of ARTI/influenza symptoms \[[@bib0055],[@bib0065]\]. There were inconsistencies in the reported effect of multivitamins on the presence/duration of fever.

Mortality rate was measured in two studies, including all-cause mortality rate \[[@bib0035]\] and infection mortality rate \[[@bib0035],[@bib0040]\]. Neither study found a significant difference between groups in participant mortality rates.

Two studies examined health service contact rate, including number of primary care contacts for infection \[[@bib0030]\], number of emergency department presentations \[[@bib0050]\], number of hospital admissions, number of days in hospital with infection \[[@bib0030]\] and number of outpatient visits for infection \[[@bib0030]\]. Neither study found a difference in health service contact rate (for any service setting) between the intervention and control groups.

One study assessed quality of life, using both the EuroQoL and SF-12 \[[@bib0030]\]. The study found no significant difference between multivitamin and placebo groups in either quality of life measure.

Antibiotic use was examined in three studies; this included the number of antibiotic prescriptions \[[@bib0030],[@bib0050]\] and number of antibiotic days \[[@bib0030],[@bib0050],[@bib0060]\]. Study findings were inconsistent, with two studies \[[@bib0030],[@bib0050]\] reporting no difference in the number of antibiotic prescriptions or days of antibiotic use between intervention and control groups, and one study \[[@bib0060]\] reporting significantly fewer days of antibiotic use among participants receiving a multivitamin relative to a calcium-magnesium supplement.

Micronutrient status (i.e. serum micronutrient measurement) was assessed in one study \[[@bib0035]\]. A significant increase in vitamin and trace element serum levels was observed in all supplementation groups over the six months of study intervention.

One study examined changes in cellular immune response (i.e. white blood cell count and activity) \[[@bib0055]\]. The study reported a significantly greater increase in total leukocyte, lymphocyte, T-lymphocyte, CD4+ and CD8+ lymphocyte and monocyte count in the intervention group after 14 days of treatment when compared with placebo. No changes were observed in T- lymphocyte activation and phagocytic activity for either groups.

Adverse events were assessed in one study \[[@bib0030]\]. Fewer adverse events were reported in the intervention group when compared with placebo (28 \[6.1%\] vs. 37 \[8.2%\] cases). These events were classed as non-serious, and included symptoms such as headache, insomnia and gout.

4. Clinical significance {#sec0060}
========================

Based on the evidence identified in this rapid review, multivitamins may be a safe and effective intervention to relieve some symptoms of ARTI, increase micronutrient status and immune function. Effects on respiratory tract infection duration and antibiotics use are inconsistent; and multivitamins do not seem to reduce health services contact or mortality. At this time, there is insufficient evidence to recommend the use of multivitamins in the treatment or prevention of COVID-19.

5. Disclaimer {#sec0065}
=============

This article should not replace individual clinical judgement. The views expressed in this rapid review are the views of the authors and not necessarily from the host institutions. The views are not a substitute for professional medical advice.
